Bye, Bye ‘Breakthrough’: Bristol, Merck HCV Drugs Face Loss Of Special Designation
Executive Summary
Recent approvals of hepatitis C treatments Sovaldi, Harvoni and Viekira Pak lead agency to reconsider ‘breakthrough’-worthiness of Bristol’s daclatasvir and Merck’s doublet therapy. FDA’s willingness to rescind shows the risk sponsors face in trying to retain the designation as other competitors reach market.
You may also be interested in...
Breakthrough Designation Rescissions: Who Might US FDA Drop Next?
Our chart details the pipeline candidates who might lose the coveted status as treatment paradigms change and trial results come in.
No Safety Shortcuts Under Breakthrough Designation, Synthetic Biologics Finds
Synthetic Biologics emerged from meetings with US FDA without its breakthrough designation, but with hope that agency will allow decoupling of safety and efficacy endpoints in planned Phase III trial for prevention of C. difficile infection.
Harvoni Approval Led To Narrowing Of Epclusa's Breakthrough Status
US FDA cited strong efficacy, good safety of Gilead's Harvoni and AbbVie's Viekira Pak in rescinding breakthrough therapy designation for the sofosbuvir/velpatasvir fixed-dose combination in hepatitis C patients with genotype 1 infection.